Tenilsetam

Drug Profile

Tenilsetam

Alternative Names: CAS 997

Latest Information Update: 04 Jul 2007

Price : $50

At a glance

  • Originator Cassella
  • Class Analgesics; Neuroprotectants
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Dementia; Diabetic retinopathy

Most Recent Events

  • 09 May 2001 Tenilsetam is being investigated for use in the prevention of diabetic retinopahy
  • 09 May 2001 Preclinical development for Diabetic retinopathy in Germany (unspecified route)
  • 22 Jan 1997 Discontinued-Clinical for Dementia in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top